Business Wire

PA-EXONE

5.8.2020 14:02:13 CEST | Business Wire | Press release

Share
ExOne Qualifies Inconel 718 for Binder Jet 3D Printing, Now Offers 22 Materials

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the nickel-based alloy Inconel 718 has been certified as Third-Party Qualified, the company’s highest designation of material readiness for its metal 3D printers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005200/en/

Frequently used in the aerospace, energy and automotive industries, Inconel 718 is known for high strength and hardness, with strong resistance to corrosion, chemicals and extreme temperatures ranging from sub-zero to 1300° F. It also has outstanding welding characteristics, and is often used for high-temperature applications, such as jet engines and tooling, or corrosive environments, such as those featuring seawater or acids.

“Today’s qualification of Inconel 718, following on the heels of M2 Tool Steel earlier this year, shows the ExOne R&D team is aggressively delivering new materials for binder jet 3D printing,” said Rick Lucas, ExOne CTO and VP, New Markets. “Our increasing pace of material qualifications is a testament to the strength of our new metal 3D printer systems equipped with Triple ACT, an advanced compaction technology that is essential for binder jetting metals and other materials at high speeds and densities.”

As is the case with Inconel 718, ExOne’s patented Triple ACT enables 3D printing of standard MIM powders, followed by standard sintering profiles and heat treatments, that deliver high-density results consistent with wrought material. Independent testing verifies that Inconel 718 3D printed and sintered by ExOne meets ASTM standard B637-18 .

“ExOne can now transition R&D materials to full qualification as demand increases,” Lucas noted.

ExOne Material Qualification Levels

ExOne has three tiers of material qualification, to signify the varying levels of readiness of materials for binder jet 3D printing applications: R&D, Customer-Qualified and Third-Party Qualified.

Previously, ExOne had recognized Inconel 718 as an R&D material, which meant it had been deemed printable for researchers, supported by ongoing development. The new Third-Party Qualified status means that the material has passed rigorous ExOne tests over multiple builds and has verified material property data from an independent third party.

Customer-Qualified materials are those that have been qualified by ExOne customers with their own standards and are being successfully printed today for their own applications. However, they have not yet earned ExOne’s highest level of qualification for general market readiness.

ExOne has an aggressive roadmap to qualify new materials based on customer demand, and frequently works with major manufacturers to develop new materials to suit specific applications.

To date, 22 metal, ceramic and composite materials are now Third-Party or Customer-Qualified. The full list is available at www.exone.com/metalmaterials .

Additionally, more than two-dozen materials are recognized as R&D ready, including aluminum, which has been fast-tracked for qualification. ExOne believes the ability to 3D print aluminum at high speeds will have a transformative, sustainable effect on the automobile and aerospace industry.

CleanFuse Enables Binder Jetting of Premium Metals

ExOne’s proprietary CleanFuse binder was a critical component in the new qualification of Inconel 718. CleanFuse is a clean-burning binder for 3D printing metals that are sensitive to carbon left behind by other binding agents during sintering.

Binder jetting is a 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.

When binders don’t burn off cleanly during sintering, carbon residue can alter the chemistry and fundamental performance of some sensitive metals. Consequently, a benefit of 3D printing metals with CleanFuse is preserving consistent part performance, including a part’s ability to be welded. This is critical for aerospace, automotive or defense applications, where parts are often integrated or assembled into a final product.

About ExOne

ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release

Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures

IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye